NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07100730 2026-03-12
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05382338 2026-02-24
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Children's Oncology Group
Phase 3 Recruiting
NCT05904119 2026-02-17
LEGATO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT05331521 2026-02-03
ImproveCodel
University Hospital Heidelberg
Phase 3 Recruiting
NCT07145112 2025-10-09
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
Phase 1 Recruiting
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT06336291 2025-01-24
GLIOSTELLA
Philogen S.p.A.
Phase 2 Recruiting
NCT04573192 2024-04-08
GLIOSTAR
Philogen S.p.A.
Phase 1/2 Recruiting
NCT05518383 2022-08-26
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4 Recruiting